Literature DB >> 19399804

National Institutes of Health consensus development conference statement: management of hepatitis B.

Michael F Sorrell1, Edward A Belongia, Jose Costa, Ilana F Gareen, Jean L Grem, John M Inadomi, Earl R Kern, James A McHugh, Gloria M Petersen, Michael F Rein, Doris B Strader, Hartwell T Trotter.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19399804     DOI： 10.1002/hep.22946

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  43 in total

Review 1.  Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.

Authors:  N Gara; X Zhao; M T Collins; W H Chong; D E Kleiner; T Jake Liang; M G Ghany; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2012-04-16       Impact factor: 8.171

3.  Role of sociocultural factors in hepatitis B screening among Asian Americans.

Authors:  Grace X Ma; Sunmin Lee; Min Wang; Yin Tan; Wanzhen Gao; Xiang Ma; Philip Lai; Jamil I Toubbeh
Journal:  South Med J       Date:  2011-07       Impact factor: 0.954

4.  Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis.

Authors:  Hong Sub Lee; Jai Keun Kim; Jae Youn Cheong; Eun Jin Han; So Yeon An; Jun Ha Song; Yun Jung Jung; Sung Chan Jeon; Min Wook Jung; Eun Jung Jang; Sung Won Cho
Journal:  Korean J Hepatol       Date:  2010-12

5.  Predictive factors of lamivudine treatment success in an hepatitis B virus-infected pediatric cohort: a 10-year study.

Authors:  Yasmine Yousef; Kathie Beland; Emmanuel Mas; Pascal Lapierre; Dorothée Bouron Dal Soglio; Fernando Alvarez
Journal:  Can J Gastroenterol       Date:  2012-07       Impact factor: 3.522

Review 6.  Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia.

Authors:  Hwai-I Yang; Mei-Hsuan Lee; Jessica Liu; Chien-Jen Chen
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 7.  Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.

Authors:  Tatyana A Shamliyan; James R Johnson; Roderick MacDonald; Aasma Shaukat; Jian-Min Yuan; Robert L Kane; Timothy J Wilt
Journal:  J Gen Intern Med       Date:  2011-01-04       Impact factor: 5.128

8.  Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy.

Authors:  Miwa Kawanaka; Ken Nishino; Jun Nakamura; Takahito Oka; Noriyo Urata; Daisuke Goto; Mitsuhiko Suehiro; Hirofumi Kawamoto; Masatoshi Kudo; Gotaro Yamada
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

9.  Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.

Authors:  Samad Amini-Bavil-Olyaee; Mihael Vucur; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 10.  Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.